Tokuç A., Dincer D., Etik D. O., Yildirim A. E., Mehdiyev S., Ari D., ...Daha Fazla
Hepatology forum, cilt.7, sa.4, ss.313-318, 2026 (ESCI, Scopus, TRDizin)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
7
Sayı:
4
-
Basım Tarihi:
2026
-
Doi Numarası:
10.14744/hf.2026.38987
-
Dergi Adı:
Hepatology forum
-
Derginin Tarandığı İndeksler:
Health Research Premium Collection (ProQuest), Scopus, Emerging Sources Citation Index (ESCI), Central & Eastern European Academic Source (CEEAS), TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.313-318
-
Akdeniz Üniversitesi Adresli:
Hayır
Özet
Background and Aim: This study evaluated the efficacy and safety of tenofovir alafenamide (TAF) in chronic hepatitis B virus-infected patients undergoing chronic hemodialysis and kidney transplant recipients.
Materials and Methods: Between January 2019 and January 2023, patients receiving TAF who were undergoing chronic hemodialysis or were kidney transplant recipients were included in a multicenter retrospective study at 17 tertiary care centers across Türkiye.
Results: A total of 58 patients were included (13 receiving hemodialysis and 45 kidney transplant recipients). The mean age of patients was 50.1±12.5 years, with a predominantly male gender (71%). At baseline, 19 patients were hepatitis B virus DNA-positive; 11 of whom were antiviral treatment-naïve. The virological response rate was 78.9% (15/19) at 12 months of TAF treatment and increased to 94.7% (18/19) by 24 months. Patients with elevated baseline alanine aminotransferase levels exhibited significant improvement after initiation of TAF. Overall, TAF was well tolerated throughout the study period, with no serious adverse events or drug discontinuations due to adverse effects.
Conclusion: TAF was associated with effective virological suppression and favorable biochemical response in patients with chronic HBV infection undergoing chronic hemodialysis and kidney transplant recipients. TAF was generally well tolerated in such patients.